5th AMR Conference – Summer Edition
Being an established platform to connect relevant AMR stakeholders from industry, SMEs, finance, hospitals, science, and policy, the 5th AMR Conference 2021 will offer three afternoons of virtual AMR briefing sessions from 24 to 26 August with high-level speakers on the most urgent topics, the AMR community is currently discussing:
- Did the COVID-19 pandemic change perceptions on the relevance and urgency of antimicrobial resistance and will new infrastructures for pandemic preparedness have an impact on dealing with AMR?
- Which new initiatives have been started to further push forward innovations in antimicrobial therapies and diagnostics?
- What updates can be provided by existing investors, funds and accelerators?
- How did policymakers in Europe and the US take over their role in establishing most needed pull incentives and what can be summarized by the first pilot running in the UK?
The 2021 summer edition of the conference, hosted by BIOCOM in cooperation with the European SME organisation BEAM Alliance, will shed light on the most recent developments in 2021. On the one hand, novel reports such as the annual antibacterial pipeline report by the World Health Organization (WHO), published in April, clearly show the still high need for novel antibiotics. According to the review, there is a near static pipeline with only few antibiotics being approved by regulatory agencies in recent years. On the other hand, major investments have pushed forward R&D in novel approaches across the globe. During the conference the global accelerator network CARB-X will summarize its achievements over the past five years, the EU-funded IMI AMR Accelerator is speaking about its first year of activities and a new incubator initiative in Europe is presenting. Investors such as the Novo Repair Impact Fund and the AMR Action Fund are looking back on 2021, and policymakers are updating on novel reimbursement schemes.
Special focus on SMEs
A special focus of the event remains on the perspective of innovative SMEs. “2021 will be a decisive year for many of us”, predicts Marc Gitzinger, Vice President of the BEAM Alliance and CEO of Swiss BioVersys. Whereas some companies recently managed to attract large rounds of financing (such as BioVersys) or funding (such as Phico Therapeutics or Summit Therapeutics), others might be forced to either down-size or close their AMR pipeline (such as X-Biotix). According to Gitzinger and his CEO colleagues, investors are becoming nervous, because governments are not ambitious enough to implement adequate pull incentives now: "We hope that policymakers learned the COVID-19 lessons."
For more information on the AMR Conference: www.amr-conference.com/